20083 ⎘
Medicinal preparations characterised by special physical form; Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles; Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction; Excipients; Inactive ingredients; Organic compounds, e.g. phospholipids, fats Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
Cellular fibronectin compositions
#302Processes for making a cellular fibronectin composition
#303METHODS AND COMPOSITIONS PRODUCED THEREBY
#304Nicotine particles
#305COMPOSITION COMPRISING BUDESONIDE FOR OPHTHALMIC USE
#306CRYSTALLIZED OXALATE DECARBOXYLASE AND METHODS OF USE
#307REHYDRATABLE, MORPHOLOGICALLY DIVERSE NANOCARRIER POWDERS
#308DRY POWDER FORMULATIONS CONTAINING LEUCINE AND TRILEUCINE
#309Starch-free soft chew for veterinary applications
#310NOVEL AEROSOL FORMULATIONS OF ONDANSETRON AND USES THEREOF
#311METHOD FOR PREPARING PHARMACEUTICAL COMPOSITIONS CONTAINING AMPHIPHILIC ACTIVE INGREDIENTS
#312IMMEDIATE RELEASE FORMULATIONS OF CANNABINOIDS
#313Pharmaceutical compositions and related methods of delivery
#314Pharmaceutical compositions and related methods of delivery
#315PARTICLES OF A MIXTURE OF IRON(III)-OXYHYDROXIDE, SUCROSE AND ONE OR MORE STARCHES, PREFERABLY OF SUCROFERRIC OXYHYDROXIDE
#316Compositions of Clofazimine, Combinations Comprising Them, Processes for Their Preparation, Uses and Methods of Treatment Comprising Them
#317NANOPARTICLE ISOFLAVONE COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME
#318A STABLE EFFERVESCENT CO-PROCESSED EXCIPIENT COMPOSITION AND A PROCESS FOR PREPARING THE SAME
#319FORMULATIONS OF 3-(6-(1-(2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL) CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL)BENZOIC ACID
#320Lanthanum Carbonate Hydroxide, Lanthanum Oxycarbonate and Methods of Their Manufacture and Use
#321Methods and compositions for treatment of pulmonary hypertension and other lung disorders
#322Compositions and methods for transplantation of colon microbiota
#323IMMEDIATE-RELEASE TABLETS CONTAINING A DRUG AND PROCESSES FOR FORMING THE TABLETS
#324ALKALINE PHOSPHATASE FORMULATIONS AND USES THEREOF
#325POWDER FOR ORAL SUSPENSION CONTAINING TADALAFIL
#326Biomarker predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment
#327Crystalline freebase forms of a biphenyl compound
#328Biphenyl compounds useful as muscarinic receptor antagonists
#329METHOD FOR THE TREATMENT OF COVID-19 INFECTIONS WITH PALMITOYLETHANOLAMIDE
#330PULMONARY PHARMACEUTICAL FORMULATIONS
#331N-PALMITOYL-ETHANOLAMIDE FOR USE IN THE PREVENTION OF COLORECTAL CARCINOMA
#332CANNABINOID COMPOSITIONS, METHODS OF MAKING SAME AND USES THEREOF
#333INTRANASAL DELIVERY OF LEVODOPA POWDER BY PRECISION OLFACTORY DEVICE
#334A STABLE LYOPHILIZED FORMULATION FOR HYBRID FC FUSED G-CSF
#335COMPOSITIONS COMPRISING ENZYME-CLEAVABLE PRODRUGS AND CONTROLLED RELEASE NAFAMOSTAT AND METHODS OF USE THEREOF
#336MODIFIED RELEASE COMPOSITIONS OF NAFAMOSTAT AND METHODS OF USING SAME
#337ORODISPERSIBLE POWDER COMPOSITION COMPRISING A TRIPTAN
#338POWDERED PLANT PREPARATION, THE MANNER IN WHICH IT IS OBTAINED, MICROGRANULES AND TABLETS OBTAINED FROM THAT PREPARATION AND THE WAYS OF PRODUCING THEM
#339BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PEDIATRIC CHOLESTATIC LIVER DISEASES
#340AMORPHOUS KINASE INHIBITOR FORMULATIONS AND METHODS OF USE THEREOF
#341AMORPHOUS KINASE INHIBITOR FORMULATIONS AND METHODS OF USE THEREOF
#342CARDIAC SARCOMERE INHIBITOR ORAL FORMULATIONS
#343Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives
#344Centanafadine pharmaceutical formulations, and methods of making and using same
#345MICRONIZED DRUG RESINATE-BASED PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREPARATION THEREOF
#346Granular Pharmaceutical Composition
#347APTAMER SPECIFICALLY BINDING TO CANCER STEM CELLS, AND USE THEREOF
#348NANOPARTICLES FOR USE IN REDIRECTION AGAINST THE TUMOUR OF A NON-TUMOUR SPECIFIC IMMUNE RESPONSE, BASED ON A PRE-EXISTING IMMUNITY
#349SPRAY DRIED FORMULATION OF A CHOLERA TOXIN B SUBUNIT VARIANT
#350BENZOAZEPINE COMPOUND-CONTAINING FREEZE-DRIED COMPOSITION
#351COMBINATION OF IBUPROFEN AND TRAMADOL FOR RELIEVING PAIN
#352Polymer protein microparticles
#353DICLOFENAC SACHET COMPOSITION
#354Pharmaceutical composition and administrations thereof
#355Pharmaceutical composition comprising GHB gastro-retentive raft forming systems having trigger pulse drug release
#356MODIFIED RELEASE DRUG POWDER COMPOSITION COMPRISING GASTRO-RETENTIVE RAFT FORMING SYSTEMS HAVING TRIGGER PULSE DRUG RELEASE
#357COMPOSITION FOR PREVENTING OR TREATING INFLAMMATION, ALLERGIES AND ASTHMA, CONTAINING VERONICASTRUM SIBIRICUM L. PENNELL AS ACTIVE INGREDIENT, AND USE THEREOF
#358Pharmaceutical Composition
#359Respiratory tract delivery of levodopa and DOPA decarboxylase inhibitor for treatment of Parkinson's disease
#360METHOD, COMPOSITION AND PACKAGE FOR BOWEL CLEANSING
#361COMPOSITION FOR REDUCING BODY FAT COMPRISING GREEN TEA EXTRACT CONTAINING GALLOCATECHIN GALLATE AS AN ACTIVE INGREDIENT AND MANUFACTURING METHOD THEREOF
#362Reduction of flake-like aggregation in nanoparticulate active agent compositions
#363Method for producing sweetener compositions and sweetener compositions
#364Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
#365WATER-SOLUBLE FORMULATIONS, METHODS OF MAKING AND USE
#366MELOXICAM CO-CRYSTAL COMPOSITIONS
#367Intranasal delivery of olanzapine by precision olfactory device
#368FORMULATIONS OF SINGLE DOMAIN ANTIGEN BINDING MOLECULES
#369Compositions, methods and uses for thermally stable multi-targeted antigens
#370Preparation method for carotenoid preparation having high bioavailability and high stability
#371Lyophilized formulations of tegavivint
#372Lyophilized formulations of tegavivint
#373Lyophilized formulations of tegavivint
#374Method and formulation for inhalation
#375Pharmaceutical composition
#376Formulations of hydroxypyridonate actinide/lanthanide decorporation agents
#377Crystalline microspheres and the process of manufacturing the same
#378INHALABLE DRY POWDER FORMULATIONS COMPRISING ANGIOGENESIS INHIBITORS
#379USE OF PEPTIDE DERIVED FROM H-REV107
#380Functional foods comprising diamine oxidase and uses thereof
#381PEPTIDE YY PHARMACEUTICAL FORMULATIONS, COMPOSITIONS, AND METHODS
#382Method of treating major depressive disorder
#383Stable Solid Formulation of GC-C Receptor Agonist Polypeptide Suitable for Oral Administration
#384METHOD OF MANUFACTURING AN ORALLY DISINTIGRATING TABLET
#385TOPICAL TREATMENT OF IMMUNE CHECKPOINT INHIBITOR INDUCED DIARRHOEA, COLITIS OR ENTEROCOLITIS USING ANTIBODIES AND FRAGMENTS THEREOF
#386EMBOLIC MICROSPHERES
#387Compositions and methods for transplantation of colon microbiota
#388PHARMACEUTICAL COMPOSITION
#389DISPIROPYRROLIDINE DERIVATIVES
#390PHARMACEUTICAL COMPOSITIONS
#391PHARMACEUTICAL COMPOSITIONS
#392PHARMACEUTICAL COMPOSITIONS
#393Orodispersible dosage unit containing an estetrol component
#394Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP)
#395Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
#396Oral Pharmaceutical Immediate Release Composition
#397Pharmaceutical composition for drug delivery
#398Methods and compositions for treatment of pulmonary hypertension and other lung disorders
#399Bendamustine pharmaceutical compositions
#400KDM1A inhibitors for the treatment of disease
#401PHARMACEUTICAL COMPOSITIONS
#402Combination formulation of two antiviral compounds
#403Preserving functionally-coated API particles produced by solventless mixing processes in aqueous suspension
#404POLYVINYL ALCOHOL-CONTAINING GRANULATED PRODUCT AND SOLID PREPARATION
#405Rapamycin for the treatment of lymphangioleiomyomatosis
#406Inhalable formulation of fluticasone propionate and albuterol sulfate
#407PHARMACEUTICAL COMPOSITIONS OF 3-(6-(1-(2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL) CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL) BENZOIC ACID AND ADMINISTRATION THEREOF
#408Amorphous kinase inhibitor formulations and methods of use thereof
#409Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
#410Crystalline freebase forms of a biphenyl compound
#411Granular Pharmaceutical Composition
#412FREEZE-DRIED ARIPIPRAZOLE FORMULATION
#413Novel formulation of metaxalone
#414Powder for oral suspension containing lamotrigine
#415Formulations of influenza therapeutics
#416Pharmaceutical formulations and uses thereof
#417STABLE MICROBIAL COMPOSITION AND DRYING PROCESS
#418Inhalable powder formulations of alginate oligomers
#419INHALATION POWDER MEDICINE, EVALUATION METHOD THEREOF, AND USE THEREOF
#420Surfactant Formulations for Inhalation
#421ESCALATING DOSING REGIMEN FOR EFFECTING WEIGHT LOSS AND TREATING OBESITY
#422Compositions comprising PGI2-receptor agonists and processes for the preparation thereof
#423Lyophilized mesenchymal stem cell derived secretome and uses thereof
#424Pharmaceutical or food supplement preparation based on alpha-lactalbumin
#425NICOTINE PARTICLES AND COMPOSITIONS
#426Microparticle Formulations for Delivery to the Lower and Central Respiratory Tract and Methods of Manufacture
#427PHARMACEUTICAL FORMULATION CONTAINING REMDESIVIR AND ITS ACTIVE METABOLITES FOR DRY POWDER INHALATION
#428NANOPARTICLE/HYDROGEL COMPLEXT FOR DRUG CARRIER
#429METHOD OF DRUG FORMULATION BASED ON INCREASING THE AFFINITY OF ACTIVE AGENTS FOR CRYSTALLINE MICROPARTICLE SURFACES
#430Orally disintegrating compositions
#431FLOWPACK FOR ORAL DELIVERY OF ACTIVE INGREDIENTS
#432BENDAMUSTINE SOLID DISPERSIONS AND CONTINUOUS INFUSION
#433Mouthwash for oral care benefits
#434Oral powder mixture with small sized particles
#435COMPOSITIONS OF SURFACE-MODIFIED THERAPEUTICALLY ACTIVE PARTICLES BY ULTRA-RAPID FREEZING
#436SOLID DISPERSION OF RIFAMYCIN-NITROIMIDAZOLE COUPLING MOLECULE AND APPLICATION THEREOF
#437Pharmaceutical Compositions Comprising Dimethyl Fumarate
#438STABILIZED FORMULATIONS OF CNS COMPOUNDS
#439PHARMACEUTICAL FORMULATIONS COMPRISING NITROCATECHOL DERIVATIVES AND METHODS OF MAKING THE SAME
#440STABILIZED COMPOSITIONS CONTAINING EDIBLE OIL AND THEIR USES IN FOOD PRODUCTS
#441Compound having TrkA inhibitory activity and pharmaceutical composition, for preventing or alleviating pain, containing same as active ingredient
#442PEPTIDE YY PHARMACEUTICAL FORMULATIONS, COMPOSITIONS, AND METHODS
#443PEDIATRIC FORMULATION OF TYROSINE KINASE INHIBITORS
#444SOLID CANNABINOID FORMULATION FOR ORAL ADMINISTRATION
#445High-concentration monoclonal antibody formulations
#446Oligosaccharide formulations of kappa opioid receptor agonists
#447Stable Solid Formulation of a GC-C Receptor Agonist Polypeptide Suitable for Oral Administration
#448THERAPEUTIC AGENT NANOPARTICLES AND METHODS OF PREPARATION
#449COMPOSITIONS AND METHODS OF USE
#450Carrier particles for dry powder formulations for inhalation
#451METHOD FOR THE PRODUCTION OF FREEZE-DRIED PELLETS COMPRISING AN ANTI-COAGULATION FACTOR XIa (FXIa) ANTIBODY
#452Compositions Comprising Guaifenesin and Eriodictyol
#453Lyophilization methods that provide stably dehydrated protozoans for use as potent live vaccines
#454VACCINE COMPOSITIONS
#455Gastro-resistant formulation containing posaconazole
#456Formulations of hydroxypyridonate actinide/lanthanide decorporation agents
#457Treatment with powdered intranasal epinephrine
#458Granules containing diamine derivative
#459Minimizing agglomeration of drug particle coating material during storage to stabilize disintegration times of pharmaceutical products
#460PRODUCTION OF ENCAPSULATED NANOPARTICLES AT COMMERCIAL SCALE
#461PHARMACEUTICAL COMPOSITION CONTAINING ILAPRAZOLE OR SALT THEREOF AND PREPARATION METHOD THEREFOR
#462Formulations of biological polymers for oral administration
#463Pharmaceutical Compositions Comprising Levocetirizine
#464METHOD FOR PRODUCING GRANULES CONTAINING A CORE PARTICLE, GRANULES CONTAINING A CORE PARTICLE, PHARMACEUTICAL COMPOSITION CONTAINING THE GRANULES CONTAINING THE CORE PARTICLE, AND PREPARATION CONTAINING THE PHARMACEUTICAL COMPOSITION
#465Compositions and methods for treating Pompe disease
#466PACKAGING BODY OF PHARMACEUTICAL COMPOSITION CONTAINING ANTITUMOR AGENT
#467METABOLITES FOR TREATMENT AND PREVENTION OF AUTOIMMUNE DISEASE
#468FORMULATIONS AND METHODS FOR LYOPHILIZATION AND LYOPHILATES PROVIDED THEREBY
#469HEAT-STABLE DRY POWDER PHARMACEUTICAL COMPOSITIONS AND METHODS
#470Conjugate of methotrexate and peptide
#471SELF-EMULSIFYING DOSAGE FORMS OF ALLERGEN AND THEIR PREPARATION THEREOF
#472Pharmaceutical formulations
#473Method of treating major depressive disorder
#474ORAL ADMINISTRABLE PHARMACEUTICAL COMPOSITION
#475Immediate release formulations of cannabinoids
#476TOPICAL INJECTABLE COMPOSITION
#477Novel formulation of meloxicam
#478FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE
#479Methods and compositions for treatment of pulmonary hypertension and other lung disorders
#480USE OF TREZASTILBENOSIDE IN MANUFACTURE OF PRODUCT FOR TREATING AND/OR PREVENTING NON-ALCOHOLIC FATTY LIVER DISEASE
#481Amorphous kinase inhibitor formulations and methods of use thereof
#482Surfactants for use in healthcare products
#483Processes for making and using a mesenchymal stem cell derived secretome
#484Dry powder formulations for inhalation
#485Process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
#486PIMOBENDAN FORMULATION AND METHOD OF USE THEREOF
#487Pharmaceutical composition
#488CANAGLIFLOZIN MONOHYDRATE AND ITS CRYSTALLINE FORMS, PREPARATION METHODS AND USES THEREOF
#489Granular Pharmaceutical Composition
#490Implantable isoxazoline pharmaceutical compositions and uses thereof
#491A STABLE PHARMACEUTICAL COMPOSITION COMPRISING PENICILLAMINE
#492Effervescent tablets that include crystalline sugar binder and methods of making the same
#493EASY-TO-TAKE GRANULAR PREPARATION AND METHOD FOR PRODUCING SAME
#494DRY POWDER VANCOMYCIN COMPOSITIONS AND ASSOCIATED METHODS
#495PHARMACEUTICAL COMPOSITIONS FOR TREATING ACID SPHINGOMYELINASE DEFICIENCY
#496Freeze-dried formulations including nanoparticles and methods of freeze-drying
#497Apixaban formulations
#498PHARMACEUTICAL COMPOSITIONS
#499Method for preserving biopharmaceuticals
#500Manufacture of degarelix
#501Pharmaceutical compositions
#502STABLE MULTIPARTICULATE PHARMACEUTICAL COMPOSITION OF ROSUVASTATIN
#503Pharmaceutical compositions
#504Radiation-Sterilized Biodegradable Drug Delivery Compositions
#505INJECTABLE NEUROSTEROID FORMULATIONS CONTAINING NANOPARTICLES
#506BACTERIOPHAGE COMPOSITIONS
#507Dry powder formulations of thymic stromal lymphopoietin (TSLP)-binding antibodies and methods of use thereof
#508Formula of neuregulin preparation
#50917-hydroxyprogesterone ester-containing oral compositions and related methods
#510Solid dosage form having excellent stability
#511Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride
#512DRY POWDER FORMULATIONS OF ALPHA-1 ANTITRYPSIN
#513Manufacture of Degarelix
#514Formulations of 6-(2-hydroxy-methylpropoxy-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
#515COMPOSITION AND METHOD FOR FREEZE-DRYING PHARMACEUTICAL COMPOSITION CONTAINING ANIONIC DRUG
#516Spray drying process with continuous preparation of spray solution
#517SOLID UNIT DOSAGE FORM FOR DOSE INDIVIDUALIZED DRUG DELIVERY
#518Pharmaceutical composition comprising GHB gastro-retentive raft forming systems having trigger pulse drug release
#519Compositions and methods for treatment
#520Processes for making and using a mesenchymal stem cell derived secretome
#521MULTIPARTICULATE FORMULATIONS OF CANNABINOIDS
#522Copper complexes for treatment of neurodegenerative disorders
#523Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride
#524MULTIPARTICULATE FORMULATIONS OF CANNABINOIDS
#525FORMULATIONS OF KINASE INHIBITORS AND PROSTANOIDS
#526METHOD AND SYSTEM FOR PRODUCING HIGH PURITY VANCOMYCIN HYDROCHLORIDE
#527TREATMENT USING DANTROLENE
#528Modified release drug powder composition comprising gastro-retentive RAFT forming systems having trigger pulse drug release
#529Solid dosage forms of (S)-ethyl 2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoate
#530BENDAMUSTINE PHARMACEUTICAL COMPOSITIONS
#531Combination formulation of two antiviral compounds
#532SUSTAINED RELEASE FORMULATIONS USING NON-AQUEOUS CARRIERS
#533Method, composition and package for bowel cleansing
#534Pharmaceutical compositions and related methods of delivery
#535Treatment of Middle East respiratory syndrome coronavirus
#536Pharmaceutical compositions
#537POLYMER-BASED SUSTAINED RELEASE DEVICE
#538Method for the Production of Commercial Nanoparticle and Microparticle Powders
#539METHOD FOR REDUCING THE RECONSTITUTION TIME OF SPRAY-DRIED PROTEIN FORMULATIONS
#540Minimizing agglomeration of drug particle coating material during storage to stabilize disintegration times of pharmaceutical products
#541FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE
#542Method for producing sweetener compositions and sweetener compositions
#543Process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
#544Oral Formulations And Uses Thereof
#545PHARMACEUTICAL COMPOUND, SALTS THEREOF, FORMULATIONS THEREOF, AND METHODS OF MAKING AND USING SAME
#546Process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
#547Pharmaceutical compositions
#548Processes for making and using a mesenchymal stem cell derived secretome
#549THYMIC STROMAL LYMPHOPOIETIN (TSLP)-BINDING MOLECULES AND METHODS OF USING THE MOLECULES
#550DICLOFENAC FORMULATIONS AND METHODS OF USE
#551Pharmaceutical compositions
#552Pharmaceutical compositions
#553METHOD FOR PRODUCING PHARMACEUTICAL COMPOSITION CONTAINING FINE PARTICLES OF POORLY SOLUBLE DRUG
#554ORAL PHARMACEUTICAL COMPOSITION AND METHOD FOR PRODUCING PARTICULATE FORMULATION COMPRISING COMPOSITION
#555Novel formulation of metaxalone
#556Crystalline freebase forms of a biphenyl compound
#557Inhalable rapamycin formulation for the treatment of pulmonary hypertension
#558Compositions and methods for delivering pharmaceutical agents
#559PHARMACEUTICAL FORMULATION
#560Pharmaceutical Compositions Comprising Levocetirizine
#561Process for Manufacturing Stable Epinephrine
#562Lycopene micro-capsule powder and preparation method thereof
#563Biphenyl compounds useful as muscarinic receptor antagonists
#564Compounds to modulate intestinal absorption of nutrients
#565Solid dispersions comprising tacrolimus
#566KDM1A inhibitors for the treatment of disease
#567Triptan Powders for Pulmonary Delivery
#568Process for the preparation of a freeze-dried pharmaceutical composition containing mitomycin C
#569Rapamycin for the treatment of lymphangioleiomyomatosis
#570Pharmaceutical JAK kinase inhibitor and diethylene glycol composition for topical administration and preparation method therefor
#571Preserving functionally-coated API particles produced by solventless mixing processes in aqueous suspension
#572Minimizing agglomeration of drug particle coating material during storage to stabilize disintegration times of pharmaceutical products
#573NOVEL AEROSOL FORMULATIONS OF ONDANSETRON AND USES THEREOF
#574OSMOTIC DRUG DELIVERY SYSTEM
#575PHARMACEUTICAL COMPOSITIONS
#576Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
#577COMPOSITIONS THAT METABOLIZE OR SEQUESTER FREE SUGAR MONOMERS AND USES THEREOF
#578SPRAY-DRIED WATER-SOLUBLE POWDER COMPOSITIONS AND PROCESSING METHODS THEREFOR
#579Granular Pharmaceutical Composition
#580Powder solid dispersions comprising quercetin, process for their preparation and formulations thereof
#581Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid and administration thereof
#582NANOPARTICULATE FORMULATION COMPRISING AN mPGES-1 INHIBITOR
#583COMBINATION FORMULATION OF TWO ANTIVIRAL COMPOUNDS
#584ESCALATING DOSING REGIMEN FOR EFFECTING WEIGHT LOSS AND TREATING OBESITY
#585POWDERED THICKENER MAINTAINING ITS EXTENSIONAL PROPERTIES WHEN RECONSTITUTED AND FOR PROMOTING SAFE SWALLOWING BY INDIVIDUALS WITH DYSPHAGIA
#586Composition for preventing or treating metabolic diseases containing artemisiae capillaris herba and citrus unshiu peel complex extracts as active ingredients
#587Formulations comprising aldosterone receptor antagonists and treatments using same
#588WATER-SOLUBLE FORMULATIONS, METHODS OF MAKING AND USE
#589Rapidly disintegrating effervescent tablets and methods of making the same
#590Effervescent tablets that include crystalline sugar binder and methods of making the same
#591TREATMENT OF HUMAN METAPNEUMOVIRUS
#592Microparticle Formulations for Delivery to the Lower and Central Respiratory Tract and Methods of Manufacture
#593CANNABINOID COMPOSITIONS AND USES
#594ORAL COMPOSITION OF EXTRACTED CANNABINOIDS AND METHODS OF USE THEREOF
#595Pharmaceutical compositions and dosage forms
#596Palatable oral veterinary compositions
#597Solid Pharmaceutical Compositions Of Androgen Receptor Antagonists
#598DRY POWDER VANCOMYCIN COMPOSITIONS AND ASSOCIATED METHODS
#599Manufacturing process of formulation having improved content uniformity
#600CANNABINOID COMPOSITIONS AND USES